GLP-1 peptides: how they work for weight loss

Unless you've been completely offline for the past two years, you've heard about Ozempic, Wegovy, and Mounjaro. These GLP-1 and dual GIP/GLP-1 medications have gone mainstream in a way few prescription drugs ever do. Celebrities discuss them openly. Social media is flooded with transformation stories. Conversations about weight loss and obesity have fundamentally shifted.

But beyond the headlines and Instagram before-and-afters, what does the science actually say about how these peptides work?

What is GLP-1?

GLP-1 (Glucagon-Like Peptide-1) is a hormone your body produces naturally. It's an incretin hormone, meaning it's released by your gut after you eat. In a healthy system, GLP-1 does several things simultaneously: it stimulates insulin secretion from the pancreas, suppresses glucagon release (which lowers blood sugar), slows gastric emptying (food moves through your stomach more slowly), and acts on brain regions involved in appetite regulation.

The key insight that launched an entire pharmaceutical revolution is that synthetic versions of GLP-1, engineered to last much longer in the body than the natural hormone, produce dramatically amplified effects on appetite and body weight.

The major GLP-1 medications

Semaglutide (Ozempic/Wegovy)

Semaglutide was developed by Novo Nordisk. Ozempic is the diabetes-indication brand; Wegovy is the obesity-indication brand. Same molecule, different dosing.

In the STEP clinical trial program, semaglutide 2.4mg weekly produced average weight loss of approximately 15–17% of body weight over 68 weeks. This was a landmark result that fundamentally changed how the medical community views pharmacological weight management.

Tirzepatide (Mounjaro/Zepbound)

Tirzepatide, developed by Eli Lilly, targets both GLP-1 and GIP receptors. This dual-agonist approach appears to produce even greater weight loss. The SURMOUNT trials showed average weight loss of 20–26% of body weight at the highest dose, putting it in territory previously only achievable through bariatric surgery.

Retatrutide (in development)

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Early Phase 2 data showed up to 24% body weight reduction at 48 weeks. This represents the next generation of these therapies.

Beyond weight loss

What's making GLP-1 medications even more significant is the emerging data on non-weight-loss benefits. Clinical evidence is accumulating for:

• Cardiovascular risk reduction (the SELECT trial showed a 20% reduction in major cardiovascular events with semaglutide)
• Kidney disease protection
• Sleep apnea improvement
• Potential benefits for MASH/NAFLD (liver disease)

This expanding indication profile is why the total addressable market for these medications is being revised dramatically upward.

The compounding pharmacy landscape

The FDA declared the semaglutide shortage "resolved" in early 2025, which effectively curtailed the ability of compounding pharmacies to produce copies of branded GLP-1 medications. This regulatory shift has significant implications for access and cost.

Compounded versions were substantially cheaper than branded products, which can exceed $1,000 per month without insurance. The closure of this pathway has created access challenges that are still being worked through.

Side effects and safety

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be worst during dose escalation and often improve over time. Side effects also follow a predictable weekly cycle after each injection, peaking in the first 48 hours and fading as drug levels stabilize.

More serious but rare concerns include pancreatitis risk, gallbladder issues, and a theoretical thyroid cancer risk based on animal studies (which led to a boxed warning, though human evidence of this risk remains limited).

Muscle mass loss is a significant concern. Studies suggest that 25–40% of weight lost on GLP-1 medications can be lean mass rather than fat. This has implications for metabolic health and is driving interest in combination approaches with resistance training, strategic protein distribution, and potentially other peptides focused on tissue repair.

The bottom line

GLP-1 peptide medications represent one of the most significant pharmaceutical developments in decades. The efficacy data is robust, the safety profile is generally favorable for the intended population, and the expanding indication data suggests benefits well beyond weight loss. However, they are prescription medications with real side effects and considerations that require medical supervision.